Inventor

BOUTROS MICHAEL

DE9 patents

⚠️ This page may combine multiple inventors who share the name “BOUTROS MICHAEL”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.

DEUTSCHES KREBSFORSCH

2 patents

US10065939B2Sep 4, 2018

Chromene derivatives and their analogs as Wnt pathway antagonists

DEUTSCHES KREBSFORSCH0 citations47

US9994854B2Jun 12, 2018

Cytotoxic T cell response modifiers

DEUTSCHES KREBSFORSCH0 citations44

BOUTROS MICHAEL

2 patents

US9371333B2Jun 21, 2016

Chromene derivatives and their analoga as Wnt pathway antagonists

BOUTROS MICHAEL0 citations42

US9062114B2Jun 23, 2015

Gpr177 as target and marker in tumors

BOUTROS MICHAEL0 citations35

FUCHS FLORIAN

1 patent

US8629272B2Jan 14, 2014

Tricyclic pyrimidine derivatives as wnt antagonists

FUCHS FLORIAN42 citations86

BASILEA PHARMACEUTICA AG

1 patent

US9970938B2May 15, 2018

Use of BUBR1 as a biomarker of drug response to furazanobenzimidazoles

BASILEA PHARMACEUTICA AG2 citations69

DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES OEFFENTLICHEN RECHTS

1 patent

US11802285B2Oct 31, 2023

Cytotoxic T cell response modifiers

DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES OEFFENTLICHEN RECHTS0 citations55

LANE HEIDI ALEXANDRA

1 patent

US10222377B2Mar 5, 2019

Use of BUBR1 as a biomarker of drug response to furazanobenzimidazoles

LANE HEIDI ALEXANDRA0 citations47

IOMX THERAPEUTICS AG

1 patent

US12338440B2Jun 24, 2025

Intracellular kinase associated with resistance against anti-tumour immune responses, and uses thereof

IOMX THERAPEUTICS AG0 citations35